US2001046982A1PendingUtilityA1
Internal 1, 15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension
Priority: Feb 1, 2000Filed: Feb 1, 2001Published: Nov 29, 2001
Est. expiryFeb 1, 2020(expired)· nominal 20-yr term from priority
A61P 43/00A61K 31/365C07D 313/00C07D 327/02A61P 27/06C07C 405/00C07D 267/00A61P 27/02C07D 321/00
44
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into ophthalmic solutions and topically applied for the treatment of the increased intraocular pressure caused by glaucoma and the reduction of ocular hypertension.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound of the general formula:
wherein X is O, S, NH or CH 2 ;
R 1 and R 2 are the same and are either H, CH 3 or F;
R 9 is H, or C 1 -C 20 straight chain, saturated or unsaturated or branched acyl;
R 11 is H, or C 1 -C 20 straight chain, saturated or unsaturated or branched acyl;
represents any combination of a single bond, or a cis or trans double bond;
Z is H, Cl, Br, I, CF 3 , CH 3 , or C 1 -C 10 straight chain or branched alkyl;
Y is O, S, NH or CH 2 .
2 . The compound of claim 1 wherein R 9 and R 11 are H; Y is O, S, or NH; and Z is CH 3 .
3 . The compound of claim 1 wherein X is CH 2 ; R 1 , R 2 is H; Y is O; and Z is CF 3 .
4 . The compound of claim 1 wherein X is CH 2 ; R 1 , R 2 is H; Y is O; and Z is Cl.
5 . The compound of claim 1 wherein X is CH 2 ; R 1 , R 2 is H; Y is CH 2 ; and Z is H.
6 . A method of treating increased intraocular pressure in the eye of a human or animal comprising the step of:
administering a therapeutically effective amount of at least one compound of the general formula to the eye: wherein X is O, S, NH or CH 2 ; R 1 and R 2 are the same and are either H, CH 3 or F; R 9 is H, or C 1 -C 20 straight chain, saturated or unsaturated or branched acyl; R 11 is H, or C 1 -C 20 straight chain, saturated or unsaturated or branched acyl; represents any combination of a single bond, or a cis or trans double bond; Z is H, Cl, Br, I, CF 3 , CH 3 , or C 1 -C 10 straight chain or branched alkyl; Y is O, S, NH or CH 2 .
7 . The method of claim 6 wherein the compound is selected from the group consisting of a 1,15-lactone of fluprostenol, a 1,15-lactone of cloprostenol, and a 1,15-lactone of latanoprost.
8 . A topical ophthalmic composition for treating increased intraocular pressure comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of the general formula:
wherein X is O, S, NH or CH 2 ;
R 1 and R 2 are the same and are either H, CH 3 or F;
R 9 is H, or C 1 -C 20 straight chain, saturated or unsaturated or branched acyl;
R 11 is H, or C 1 -C 20 straight chain, saturated or unsaturated or branched acyl;
represents any combination of a single bond, or a cis or trans double bond;
Z is H, Cl, Br, I, CF 3 , CH 3 , or C 1 -C 10 straight chain or branched alkyl;
Y is O, S, NH or CH 2 .
9 . The topical ophthalmic composition of claim 8 wherein the compound is selected from the group consisting of a 1,15-lactone of fluprostenol, a 1,15-lactone of cloprostenol, and a 1,15-lactone of latanoprost.
10 . A topical formulation for treating increased intraocular pressure comprising the following ingredients by weight percent:
Fluprostenol 1,15-lactone
0.002
Dextran 70
0.1
Hydroxypropyl Methylcellulose
0.3
Sodium Chloride
0.77
Potassium Chloride
0.12
Disodium EDTA
0.05
Benzalkonium Chloride
0.01
HCl and/or NaOH
to pH = 7.0-7.6
Purified water
q.s. to 100%Join the waitlist — get patent alerts
Track US2001046982A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.